Skip to main content

Table 1 Primary aim of different therapeutics addressing the four pillars of successful immune-mediated cancer rejection

From: Shifting the paradigm: engaging multicellular networks for cancer therapy

  1. Scoring based on technical assessment of the functional potential of an optimized product
  2. ? Conditional effect beyond direct scope of therapeutic determined by the induction of pro-inflammatory signals by dying cancer cells (Example is in Fig. 1 D); $ Depending upon quality of product before administration and favorable TME conditions
  3. mAbs/engagers include multi-specific mAbs including and CD3-based T cell engagers and similar. ADC = antibody drug conjugates
  4. Genetic payloads include methods for delivery of genetic material short of cellular product or molecularly engineered nanoparticles
  5. Basic CAR Cell (CAR-carrying cell products) with no enhancements based on modern synthetic biology approaches [47]
  6. Armored CAR-T (or other cell products) = next generation CAR-T cells or other cell products that may include conditional and reversible gene activation, logic gating for accurate tumor antigen recognition [47]
  7. Targeted delivery = nanoparticles molecularly engineered to deliver anti-tumoral payloads[48]